Proportion of patients with no radiographic progression at week 48
| N/N-obs | Week 48 (LE) | Week 48 (observed/LOCF) | ||||
| Placebo* 228/192 | Baricitinib 2 mg 229/218 | Baricitinib 4 mg 227/204 | Placebo* 228/204 | Baricitinib 2 mg 229/219 | Baricitinib 4 mg 227/206 | |
| ΔmTSS, n (%) | ||||||
| ≤0 | 150/192 (78.1) | 175/218 (80.3) | 169/204 (82.8) | 151/204 (74.0) | 172/219 (78.5) | 169/206 (82.0) |
| ≤0.5 | 150/192 (78.1) | 183/218 (83.9) | 174/204 (85.3) | 166/204 (81.4) | 188/219 (85.8) | 179/206 (86.9) |
| ≤SDC (1.7) | 158/192 (82.3) | 190/218 (87.2) | 183/204 (89.7)† | 174/204 (85.3) | 197/219 (90.0) | 190/206 (92.2)† |
The response status is dichotomised from the change in mTSS that is imputed using LE or LOCF. Comparisons analysed using logistic regression model.
*These patients were initially randomised to placebo, but switched to baricitinib 4 mg at rescue or at week 24 prior to entry to RA-BEYOND.
†P ≤ 0.05 vs placebo.
Δ, change from baseline; LE, linear extrapolation; LOCF, last observation carried forward; mITT, modified intent-to-treat; mTSS , modified Total Sharp Score; n, number of mITT patients; N-obs, number of patients with non-missing baseline and ≥1 non-missing postbaseline mTSS data included in analysis; SDC, smallest detectable change.